Developing new drugs to treat hearing disorders and serious diseases of the central nervous system

News & Events

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutics regains rights to clinical stage Kv3 programme https://t.co/rBHjjR7aC0
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more. Barbara's experience… https://t.co/u0VXnvXlGI
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing… https://t.co/oeGgN4ooWG
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image